Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127538811 | 12753881 | 1 | I | 20160823 | 20160916 | 20160916 | EXP | US-ROCHE-1829208 | ROCHE | 56.00 | YR | M | Y | 77.00000 | KG | 20160916 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127538811 | 12753881 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE 1 | 125085 | 1892 | MG | ||||||||
| 127538811 | 12753881 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE 2 | 125085 | 866 | MG | ||||||||
| 127538811 | 12753881 | 3 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 1 | 0 | 100 | MG | ||||||||
| 127538811 | 12753881 | 4 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 2 | 0 | 100 | MG | ||||||||
| 127538811 | 12753881 | 5 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 3 | 0 | 100 | MG | ||||||||
| 127538811 | 12753881 | 6 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 4 | 0 | 75 | MG | ||||||||
| 127538811 | 12753881 | 7 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 5 | 0 | 75 | MG | ||||||||
| 127538811 | 12753881 | 8 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 6 | 0 | 100 | MG | ||||||||
| 127538811 | 12753881 | 9 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 7 | 0 | 100 | MG | ||||||||
| 127538811 | 12753881 | 10 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 8 | 0 | 100 | MG | ||||||||
| 127538811 | 12753881 | 11 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 9 | 0 | 100 | MG | ||||||||
| 127538811 | 12753881 | 12 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE 10, LAST TREATMENT DATE: 26/OCT/2010 | 0 | 100 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127538811 | 12753881 | 1 | Carcinoid tumour |
| 127538811 | 12753881 | 3 | Carcinoid tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127538811 | 12753881 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127538811 | 12753881 | Hyperglycaemia | |
| 127538811 | 12753881 | Wound dehiscence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127538811 | 12753881 | 1 | 20100112 | 0 | ||
| 127538811 | 12753881 | 2 | 20100209 | 0 | ||
| 127538811 | 12753881 | 3 | 20100112 | 0 | ||
| 127538811 | 12753881 | 4 | 20100209 | 0 | ||
| 127538811 | 12753881 | 5 | 20100316 | 0 | ||
| 127538811 | 12753881 | 6 | 20100413 | 0 | ||
| 127538811 | 12753881 | 7 | 20100518 | 0 | ||
| 127538811 | 12753881 | 8 | 20100615 | 0 | ||
| 127538811 | 12753881 | 9 | 20100713 | 0 | ||
| 127538811 | 12753881 | 10 | 20100810 | 0 | ||
| 127538811 | 12753881 | 11 | 20100907 | 0 | ||
| 127538811 | 12753881 | 12 | 20101005 | 0 |